[{"data":1,"prerenderedAt":237},["ShallowReactive",2],{"compound-retatrutide":3,"compound-related-retatrutide":212,"compound-reading-retatrutide":225},{"id":4,"title":5,"alsoKnownAs":6,"body":7,"casNumber":60,"category":181,"description":171,"extension":182,"faq":183,"meta":193,"molecularFormula":194,"molecularWeight":76,"name":5,"navigation":195,"path":196,"presentations":197,"purity":199,"rank":200,"relatedCompounds":201,"relatedResearch":204,"seo":208,"sequence":194,"stem":209,"summary":210,"__hash__":211},"compounds\u002Fcompounds\u002Fretatrutide.md","Retatrutide","LY3437943",{"type":8,"value":9,"toc":170},"minimark",[10,15,19,22,26,101,105,108,111,115,118,121,125,128,135,141,153,157,160,163,167],[11,12,14],"h2",{"id":13},"what-retatrutide-is","What retatrutide is",[16,17,18],"p",{},"Retatrutide, development code LY3437943, is a synthetic peptide engineered to\nactivate three metabolic receptors from a single molecule: the glucagon-like\npeptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide\nreceptor (GIPR), and the glucagon receptor (GCGR).",[16,20,21],{},"It represents the third step in a clear line of development. Single GLP-1\nagonists came first, dual GLP-1\u002FGIP agonists followed, and retatrutide adds\nglucagon receptor activity to the same backbone strategy. Each step has been an\nattempt to recruit more of the endogenous incretin and glucoregulatory system\nfrom one injectable molecule rather than combining agents.",[11,23,25],{"id":24},"molecular-profile","Molecular profile",[27,28,29,42],"table",{},[30,31,32],"thead",{},[33,34,35,39],"tr",{},[36,37,38],"th",{},"Property",[36,40,41],{},"Value",[43,44,45,53,61,69,77,85,93],"tbody",{},[33,46,47,51],{},[48,49,50],"td",{},"Development code",[48,52,6],{},[33,54,55,58],{},[48,56,57],{},"CAS number",[48,59,60],{},"2381089-83-2",[33,62,63,66],{},[48,64,65],{},"Receptor targets",[48,67,68],{},"GLP-1R, GIPR, GCGR",[33,70,71,74],{},[48,72,73],{},"Molecular weight",[48,75,76],{},"~4,731 Da",[33,78,79,82],{},[48,80,81],{},"Modification",[48,83,84],{},"C20 fatty-diacid conjugation",[33,86,87,90],{},[48,88,89],{},"Circulating half-life",[48,91,92],{},"~6 days (albumin binding via the fatty acid)",[33,94,95,98],{},[48,96,97],{},"Appearance",[48,99,100],{},"White to off-white lyophilised powder",[11,102,104],{"id":103},"why-the-third-receptor-matters","Why the third receptor matters",[16,106,107],{},"GLP-1 receptor activity drives the insulinotropic and satiety-associated effects\nthat made the first generation of these compounds interesting. GIP receptor\nactivity appears to complement it, with published dual-agonist data showing\ngreater effect than GLP-1 activity alone.",[16,109,110],{},"The glucagon receptor is the counterintuitive addition. Glucagon opposes insulin\nand raises hepatic glucose output, which reads as the wrong direction for a\nmetabolic agent. The rationale is that glucagon receptor activation also\nincreases energy expenditure and promotes hepatic lipid oxidation, and that when\nit is combined with sufficient GLP-1 and GIP activity, the glucose-raising\ncomponent is offset while the energy-expenditure and liver-fat effects remain.\nWhether that balance holds across models is precisely what the compound is\nstudied to establish.",[11,112,114],{"id":113},"research-context","Research context",[16,116,117],{},"Phase 2 clinical data published in 2023 reported dose-dependent reductions in\nbody weight over 48 weeks, alongside improvements in glycaemic markers in\nparticipants with type 2 diabetes and reductions in liver-fat fraction. In\npreclinical and in-vitro work, retatrutide is used to probe the pharmacology of\ncombined incretin and glucagon signalling — receptor binding and selectivity\nassays, cAMP accumulation as a functional readout of receptor activation, and\ncomparative work against single and dual agonists.",[16,119,120],{},"Tested Peptides supplies retatrutide as a chemical reference material for\nin-vitro laboratory research. Nothing on this page is a therapeutic claim, and\nno dosing or administration guidance is provided.",[11,122,124],{"id":123},"analytical-notes","Analytical notes",[16,126,127],{},"Retatrutide is a large, fatty-acid-conjugated peptide, and both properties bear\non how it is characterised.",[16,129,130,134],{},[131,132,133],"strong",{},"Purity by HPLC."," Reversed-phase separation of a lipidated peptide of this\nsize tends to produce a broader main peak than an unmodified short peptide, and\nthe impurity profile of interest sits close to the main peak — deletion\nsequences missing a single residue, and species where the fatty-acid conjugation\nis incomplete or has occurred at the wrong position. A purity figure quoted\nwithout the chromatogram behind it hides exactly that detail.",[16,136,137,140],{},[131,138,139],{},"Identity by mass spectrometry."," Confirming observed mass against theoretical\nmass is what distinguishes correctly assembled retatrutide from a related\nincretin analogue. The compounds in this class share substantial sequence\nhomology, and chromatography alone will not reliably separate the question of\n\"how pure\" from the question of \"pure what\".",[16,142,143,146,147,152],{},[131,144,145],{},"Net peptide content."," Like most synthetic peptides, retatrutide is supplied\nas a salt with residual water, so gross vial mass exceeds peptide mass. Where\nmolar precision matters, work from the net peptide content on the Certificate of\nAnalysis rather than the label figure — see\n",[148,149,151],"a",{"href":150},"\u002Fresearch\u002Fnet-peptide-content-vs-purity","net peptide content versus purity",".",[11,154,156],{"id":155},"handling-and-storage","Handling and storage",[16,158,159],{},"Store the sealed vial at −20 °C, protected from light and moisture. Allow it to\nreach room temperature before opening, so that atmospheric moisture does not\ncondense onto cold lyophilised cake.",[16,161,162],{},"Fatty-acid-conjugated peptides are unusually susceptible to interfacial\naggregation. Add diluent slowly down the inside wall of the vial rather than\ndirectly onto the cake, and swirl gently — never shake or vortex. Store\nreconstituted solution at 2–8 °C, protected from light, and avoid repeated\nfreeze-thaw cycles.",[11,164,166],{"id":165},"what-we-supply","What we supply",[16,168,169],{},"Retatrutide is released against a ≥99% purity specification, with in-house HPLC\nand mass spectrometry on every batch and a batch-specific Certificate of\nAnalysis carrying the batch number printed on the vial. Select batches\nadditionally receive independent purity verification by a third-party\nlaboratory. Ordering opens at launch; nothing is released before the analysis is\nin hand.",{"title":171,"searchDepth":172,"depth":172,"links":173},"",2,[174,175,176,177,178,179,180],{"id":13,"depth":172,"text":14},{"id":24,"depth":172,"text":25},{"id":103,"depth":172,"text":104},{"id":113,"depth":172,"text":114},{"id":123,"depth":172,"text":124},{"id":155,"depth":172,"text":156},{"id":165,"depth":172,"text":166},"Metabolic","md",[184,187,190],{"question":185,"answer":186},"What is retatrutide studied for?","Retatrutide is studied in metabolic research as a triple receptor agonist. Published preclinical and clinical work has examined body-weight, glucose-homeostasis, energy-expenditure and hepatic-fat endpoints. Tested Peptides supplies it for in-vitro laboratory research only and makes no therapeutic claims.",{"question":188,"answer":189},"How does retatrutide differ from tirzepatide?","Tirzepatide activates two receptors, GLP-1 and GIP. Retatrutide adds a third, the glucagon receptor. The glucagon component is the pharmacologically distinguishing feature and is associated in published data with effects on energy expenditure and hepatic fat that dual agonists do not produce.",{"question":191,"answer":192},"Why is retatrutide harder to handle than an unmodified peptide?","It carries a C20 fatty-diacid conjugate, which is what gives it a long circulating half-life through albumin binding. That same lipophilic tail makes the molecule prone to accumulating at air-liquid interfaces, so agitation during reconstitution causes aggregation more readily than it would with a plain peptide. Add diluent down the vial wall and swirl rather than shake.",{},null,true,"\u002Fcompounds\u002Fretatrutide",[198],"10 mg vial","≥99%",1,[202,203],"tirzepatide","semaglutide",[205,206,207],"net-peptide-content-vs-purity","peptide-aggregation-and-handling","how-to-read-a-peptide-coa",{"title":5,"description":171},"compounds\u002Fretatrutide","A single-molecule GLP-1, GIP and glucagon receptor triple agonist, the third generation of incretin-based metabolic research peptides.","E2N43R5d2-Sgyzl0o8YqwcbR2QNX8_gczNXAidisij0",[213,219],{"path":214,"name":215,"alsoKnownAs":216,"summary":217,"category":181,"molecularWeight":218,"purity":199},"\u002Fcompounds\u002Fsemaglutide","Semaglutide","GLP-1 receptor agonist","A long-acting GLP-1 receptor agonist and the reference single-agonist compound in incretin research.","~4,114 Da",{"path":220,"name":221,"alsoKnownAs":222,"summary":223,"category":181,"molecularWeight":224,"purity":199},"\u002Fcompounds\u002Ftirzepatide","Tirzepatide","LY3298176 · GIP\u002FGLP-1 dual agonist","A dual GIP and GLP-1 receptor agonist, the second-generation incretin analogue and the reference compound for comparative metabolic work.","~4,813 Da",[226,230,233],{"path":227,"title":228,"description":229},"\u002Fresearch\u002Fhow-to-read-a-peptide-coa","How to Read a Peptide Certificate of Analysis","A field-by-field walkthrough of a peptide COA — what each number establishes, which fields are load-bearing, and what a missing batch number tells you about the rest of the document.",{"path":150,"title":231,"description":232},"Net Peptide Content vs Purity: The Two Numbers Everyone Confuses","A vial can be 99% pure and still contain 25% less peptide than the label says. Why purity and net peptide content are different measurements, and which one your concentration calculation actually needs.",{"path":234,"title":235,"description":236},"\u002Fresearch\u002Fpeptide-aggregation-and-handling","Why Peptide Solutions Go Cloudy: Aggregation and Handling","Shaking a reconstituted peptide is the most common way to ruin one. The interfacial mechanism behind aggregation, why lipidated peptides are worse, and the handling practice that follows from it.",1787473952615]